PRESS RELEASES
| Back |
| Amylin Comments on RiskMetrics Report |
Urges Stockholders to Vote FOR Amylin Director Nominees on the Blue Proxy Card Today RiskMetrics Splits Recommendation in Proxy Contest It is important for shareholders to note that Importantly, Amylin's Board and management team have recognized and
embraced the need for change, with two new independent Director nominees, Over the course of the past six months, Amylin has also taken the necessary steps to effect change in its business strategy and increase long-term shareholder value, including:
-- Early submission of the New Drug Application (NDA) for exenatide once
weekly to
Amylin's Board is committed to representing the interests of ALL Amylin shareholders. We urge shareholders to act now to maximize the value of their investment and not risk the Company's future and prospects. Amylin shareholders should vote FOR Amylin's Director nominees on the BLUE proxy card today. Your Vote Is Important, No Matter How Many Or How Few Shares You Own If you have questions about how to vote your shares, or need additional assistance, please contact the firm assisting us in the solicitation of proxies:
INNISFREE M&A INCORPORATED
Stockholders Call Toll-Free: (877) 717-3926
Banks and Brokers Call Collect: (212) 750-5833
IMPORTANT
We urge you NOT to vote using any White or Gold proxy card sent to you by
Icahn or Eastbourne, as doing so will revoke your vote on the BLUE proxy card. If you have already done so, you have every legal right to change your vote by using the enclosed BLUE proxy card to vote today--by telephone, by Internet, or by signing, dating and returning the BLUE proxy card in the postage-paid envelope provided. About Amylin Forward Looking Statements This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. Our actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks that BYETTA, SYMLIN or exenatide once weekly may be affected by competition, unexpected new data, safety and technical issues, or manufacturing and supply issues; risks that our financial results may fluctuate significantly from period to period and may not meet market expectations; risks that any financial guidance we provide may not be accurate; risks that our clinical trials will not be completed when planned, may not replicate previous results or achieve desired end-points; risks that our preclinical studies may not be predictive; risks that our NDAs for product candidates or sNDAs for label expansion requests, such as the exenatide once weekly NDA mentioned in this letter, may not be submitted timely or receive FDA approval; risks that our expense reductions will not be as large as we expect; risks that the restructured operations for exenatide will not produce the results we expect; and other risks inherent in the drug development and commercialization process. Commercial and government reimbursement and pricing decisions and the pace of market acceptance may also affect the potential for BYETTA, SYMLIN or exenatide once weekly. These and additional risks and uncertainties are described more fully in the Company's most recently filed Form 10-K and Form 10-Q. Amylin disclaims any obligation to update these forward-looking statements. Additional Information and Where To Find It This press release may be deemed to be solicitation material in respect of
the matters to be considered at the 2009 Annual Meeting of Stockholders.
Amylin has filed the definitive proxy statement with the Participants in Solicitation Amylin and its directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the matters to be considered at the 2009 Annual Meeting of Stockholders. Information regarding the interests of Amylin's directors and executive officers in the proxy contest is included in Amylin's definitive proxy statement.
CONTACTS:
SOURCE |